Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Cents and Sensibility - Kimberly and Friends' Consortium -- Ignore unavailable to you. Want to Upgrade?

To: Wes Stevens who wrote (61627)	1/12/2000 6:07:00 PM
From: Mr. Big	Read Replies (2) \| Respond to of 108040

Think ISIP has one more press release to let here spread her wings: DESCRIPTION PRESS RELEASE DATE » Antisense Drug Causes Reduction of C-Raf-1 RNA Levels in Cancer Patients January 12, 2000 » Isis Forms Collaboration with Elan to Develop Antisense Drug for Hepatitis C January 6, 2000 » Isis Announces Disappointing Results from ISIS 2302 Clinical Trial in Crohn's Disease December 15, 1999 » Isis Begins Phase IIa Study of ISIS 2302 for Psoriasis December 9, 1999 » Isis Begins Phase IIa Study of ISIS 2302 for Ulcerative Colitis December 7, 1999 » Isis Announces Financing Facility Commitment up to $120 Million November 22, 1999 » Isis to Proceed with Development of ISIS 3521 and ISIS 5132 as Novartis Concludes Participation November 22, 1999 » Isis Pharmaceuticals Announces Plans to Initiate Phase III Trials of ISIS 3521 November 22, 1999 » Isis Announces Allowance of 450th Patent November 16, 1999 » Isis Presents Data from Phase II Trial of ISIS 2302 in Rheumatoid Arthritis November 15, 1999 » Isis Demonstrates "Switching" of Key Gene Stimulates Effects of Chemotherapeutic Agents November 8, 1999 » Isis Pharmaceuticals Reports Third Quarter 1999 Results October 28, 1999 » Isis and Rhône-Poulenc Rorer Establish Antisense Target Validation Collaboration September 29, 1999 » Isis Pharmaceuticals and Abbott Laboratories Establish Manufacturing Collaboration for Antisense Drugs September 13, 1999 » Ibis Therapeutics, A Division of Isis Pharmaceuticals, Creates New Method to Discover RNA-Binding Drugs September 8, 1999 » Isis in Late Stage Negotiations to Commercialize ISIS 2302 September 2, 1999 » Isis Reacquires Full Rights to ISIS 2302 September 2, 1999 » European Approval of VitraveneTM Triggers $2.5 MM Milestone for Isis August 04, 1999 » Isis Pharmaceuticals Reports Second Quarter 1999 Results July 29, 1999 » Isis Presents Safety and Preliminary Activity Data on Three Antisense Cancer Drugs at ASCO May 18, 1999 » Isis Begins Phase II Testing of Third Anticancer Drug, ISIS 2503 May 10, 1999 » Isis Pharmaceuticals Reports First Quarter 1999 Results April 28, 1999 » Isis and CIBA Vision Announce European CPMP Recommends Approval of VitraveneÔ for Pateints with Both Newly Diagnosed and Advanced CMV Retinitis April 28, 1999 » Isis and Elan Form Partnership to Develop Oral Antisense Drugs; TNF-alpha Inhibitor is First Drug Candidate April 12, 1999 » Ibis Therapeutics, A Division of Isis Pharmaceuticals, Receives $6.6 Million Defense Department Grant To Discover Biological Warfare Drug Countermeasures March 4, 1999 » Isis Reports Year End and Fourth Quarter Results for 1998 February 17, 1999 » Debby Jo Blank Joins Isis Pharmaceuticals as Executive Vice President February 17, 1999 » Isis Announces Organizational Changes February 1, 1999 » Isis and Abbott Establish Target Validation Collaboration January 12, 1999 » Isis and Zeneca Establish Antisense Drug Discovery Collaboration to Develop Cancer Therapeutics December 21, 1998 » Isis Acquires Antisense Patent and Technology Estate from Gilead Sciences December 18, 1998 » Isis Wins Industry Week Magazine's Technology and Innovation Award December 17, 1998 » Isis Pharmaceuticals' CEO To Be Honored By Crohn's and Colitis Foundation of America December 10, 1998 » Isis Sublicences PNA Technology Patent to Pantheco A/S To Develop Anti-Infective Agents November 16, 1998 » Isis Pharmaceuticals Reports Third Quarter 1998 Results November 03, 1998 » Isis Achieves $7.5 Million Milestone for FDA Approval of Antisense CMV Retinitis Drug isip.com